The next battle in obesity treatment is no longer simply GLP-1 vs. GLP-1.

Between 2026 and 2030, competition is likely to be defined by a much broader set of factors: efficacy, convenience, tolerability, treatment persistence, manufacturing scalability, reimbursement and global access.

The obesity-drug pipeline is rapidly evolving beyond traditional weekly injectable GLP-1 therapies. Pharmaceutical companies are advancing oral GLP-1 therapies, dual and triple receptor agonists, GLP-1/amylin combinations and other multi-pathway metabolic medicines.

For pharmaceutical companies, biotech developers, investors, CDMOs and healthcare strategists, the critical question is no longer simply which drug produces the greatest weight loss.

It is:

Which therapeutic platform can deliver the strongest combination of clinical outcomes and commercial scalability?

Oral GLP-1 Therapies Could Change Obesity Treatment Adoption

One of the biggest developments in the obesity-treatment market is the emergence of oral GLP-1 therapies.

Eli Lilly’s orforglipron, marketed as Foundayo, represents an important development in this category. FDA approval in 2026 for chronic weight management in adults with obesity, or overweight with a weight-related comorbidity, gives patients an oral alternative to injectable therapies.

The once-daily formulation could address one of the major barriers associated with injectable treatment: administration preference and convenience.

Lilly has reported meaningful weight reduction with orforglipron in clinical development, including results in older adults without type 2 diabetes.

The commercial implication is significant.

A larger proportion of patients may be willing to initiate treatment if obesity medicines become easier to administer and integrate into everyday life.

The strategic question

Can oral obesity medicines expand the treated patient population rather than simply compete for patients already using injectable therapies?

That distinction could determine the size of the next market opportunity.

What Comes After Oral GLP-1?

The next generation of obesity medicines is becoming increasingly sophisticated.

Rather than focusing exclusively on GLP-1 receptor activation, drug developers are combining multiple metabolic pathways to potentially improve weight reduction, metabolic health and treatment durability.

Novo Nordisk: Zenagamtide and CagriSema

Novo Nordisk is advancing zenagamtide, formerly known as amycretin.

Zenagamtide is designed as a unimolecular GLP-1/amylin receptor agonist, with both oral and injectable development programs.

The company is also advancing CagriSema, a combination of semaglutide and cagrilintide.

CagriSema remains one of the most closely watched next-generation obesity programs. In the REDEFINE 4 trial, it produced substantial weight loss, although it did not meet the study’s non-inferiority endpoint against tirzepatide 15 mg.

This highlights an increasingly important reality in obesity drug development:

A new therapy must demonstrate not only strong efficacy, but meaningful differentiation against increasingly effective competitors.

Eli Lilly’s Retatrutide: The Triple-Agonist Opportunity

Eli Lilly’s retatrutide is another major program in the next generation of obesity therapeutics.

Unlike conventional GLP-1 therapies, retatrutide targets three metabolic pathways:

• GIP
• GLP-1
• Glucagon

This triple-agonist mechanism is designed to produce broader metabolic effects and has generated substantial interest because of the magnitude of weight reduction observed during clinical development.

If late-stage studies confirm its efficacy, safety and durability, retatrutide could become an important component of Lilly’s long-term obesity portfolio.

The strategic significance goes beyond one molecule.

It demonstrates how competition is moving toward multi-receptor pharmacology.

New Entrants Are Expanding the Competitive Landscape

The obesity pipeline is no longer dominated exclusively by Novo Nordisk and Eli Lilly.

Boehringer Ingelheim, for example, is advancing BI 3034701, a next-generation multi-receptor approach involving GLP-1, GIP and NPY2 pathways.

The emergence of additional mechanisms could create a more fragmented competitive environment between 2026 and 2030.

This could ultimately give physicians more options for matching therapies with different patient profiles.

The Key Questions for Obesity Drug Decision-Makers

For pharmaceutical executives, investors and healthcare strategists, the most important questions are becoming increasingly commercial.

Which companies are developing oral GLP-1 therapies?

Eli Lilly currently has one of the most prominent commercial positions with orforglipron, while other pharmaceutical companies continue to develop oral small-molecule and peptide-based obesity therapies.

What are the major oral GLP-1 therapies in development?

The pipeline increasingly includes once-daily oral candidates designed to combine meaningful weight reduction with improved administration convenience.

What is happening with multi-receptor agonists?

Drug developers are increasingly investigating combinations and multi-receptor molecules involving GLP-1, GIP, glucagon, amylin and other metabolic pathways.

What are Eli Lilly’s key next-generation obesity assets?

Lilly’s obesity strategy extends beyond Mounjaro and Zepbound, with orforglipron and retatrutide representing important next-generation opportunities.

What are Novo Nordisk’s next-generation programs?

Novo Nordisk is developing zenagamtide and CagriSema, alongside its established semaglutide-based portfolio.

The Next Obesity Drug Battle Will Not Be Decided by Weight Loss Alone

Historically, obesity-drug competition has focused heavily on one question:

How much weight does the patient lose?

That is changing.

By 2030, competitive differentiation could increasingly depend on a broader combination of clinical and commercial factors.

Key competitive dimensions include:

• Weight-loss efficacy
• Oral vs. injectable administration
• Gastrointestinal tolerability
• Treatment persistence
• Lean-mass preservation
• Cardiovascular outcomes
• Metabolic outcomes
• Potential kidney and liver benefits
• Dosing frequency
• Manufacturing complexity
• Cost of treatment
• Insurance coverage and reimbursement
• Patient willingness to initiate therapy
• Long-term adherence
• Physician prescribing behaviour
• Global supply capacity

This means the strongest molecule on paper may not automatically become the strongest commercial product.

Patient Behaviour Could Become a Major Competitive Differentiator

The next phase of the obesity market will increasingly depend on patient behaviour.

Patients may evaluate therapies based on:

“How much weight will I lose?”

but also:

“Do I have to inject it?”

“How frequently do I need to take it?”

“What side effects should I expect?”

“Can I afford it long term?”

“Will I be able to stay on treatment?”

These behavioural factors could have a major impact on treatment initiation, persistence and ultimately pharmaceutical revenue.

For manufacturers, understanding patient willingness to start and remain on therapy could become as important as understanding clinical efficacy.

Buyer Intelligence: Who Will Influence the Market?

The obesity-treatment ecosystem extends well beyond pharmaceutical companies.

Physicians

Endocrinologists, obesity-medicine specialists, primary-care physicians and cardiometabolic specialists will influence treatment selection and adoption.

Patients

Patients will increasingly compare convenience, affordability, tolerability and expected outcomes.

Payers

Payers will focus on:

• Total treatment cost
• Cardiometabolic outcomes
• Hospitalization avoidance
• Long-term healthcare expenditure
• Treatment persistence
• Comparative effectiveness

Employers

As obesity-related healthcare costs increasingly affect employer-sponsored insurance, employers may become more active stakeholders in access and coverage decisions.

Investors

Investors will increasingly evaluate obesity companies based not only on pipeline efficacy but also on:

manufacturing capacity + market access + competitive differentiation + lifecycle strategy.

Manufacturing and CDMO Opportunities

The rapid expansion of obesity therapeutics is also creating opportunities across the pharmaceutical manufacturing ecosystem.

Demand could increase for:

• API manufacturing
• Peptide manufacturing
• Oral small-molecule production
• Injectable drug-product manufacturing
• Formulation development
• Analytical development
• GMP manufacturing
• Fill-finish
• Scale-up
• Technology transfer
• Packaging
• Stability testing
• Supply-chain management

For CDMOs and CMOs, the growth of oral and multi-pathway obesity medicines could create new opportunities beyond traditional peptide manufacturing.

Manufacturing scalability may ultimately become one of the biggest constraints – and competitive advantages – in the obesity-drug market.

TAM, SAM and SOM: Where Is the Real Opportunity?

From a commercial-intelligence perspective, the obesity market should not be viewed as one homogeneous opportunity.

TAM — Total Addressable Market

The TAM includes the broad population of adults living with obesity or overweight who could potentially benefit from pharmacological treatment.

SAM — Serviceable Available Market

The SAM is narrower and depends on:

• Approved indications
• Clinical eligibility
• Physician willingness to prescribe
• Payer coverage
• Geographic availability
• Patient affordability
• Treatment tolerability

SOM — Serviceable Obtainable Market

The actual obtainable opportunity depends on:

• Brand awareness
• Clinical differentiation
• Pricing
• Reimbursement
• Manufacturing capacity
• Physician adoption
• Patient persistence
• Competitive intensity
• Distribution capabilities

This is why headline market-size forecasts alone are insufficient for strategic decision-making.

What Does This Mean for Pharma and Biotech?

The obesity market is transitioning from a single-mechanism race toward a broader metabolic-therapeutics ecosystem.

The competitive landscape now includes:

GLP-1 agonists

GIP/GLP-1 dual agonists

GLP-1/amylin combinations

Triple agonists

Oral GLP-1 therapies

Next-generation multi-receptor therapies

The winners between 2026 and 2030 may therefore be companies that successfully combine clinical differentiation, patient convenience, manufacturing scale and market access.

Where Towards Healthcare Research & Consulting Can Help

At Towards Healthcare Research & Consulting, we help pharmaceutical, biotech, CDMO, investor and healthcare organizations understand the commercial opportunities emerging across obesity therapeutics.

Our research capabilities include:

• TAM / SAM / SOM analysis
• Competitive intelligence
• Pipeline and clinical-trial tracking
• Buyer intelligence
• Patient and physician behaviour analysis
• Pricing and reimbursement analysis
• Company benchmarking
• Market-entry strategy
• CDMO and manufacturing opportunity assessment
• Regional opportunity mapping
• Strategic partner identification

The most important question is no longer:

“How big will the GLP-1 market become?”

The more strategic question is:

“Where will the next high-value opportunity emerge within the obesity-treatment ecosystem?”

That is the intelligence pharmaceutical and healthcare leaders need before making their next move.